 Up to 462 patients 18 years of age and older, with confirmed clinical diagnosis of rosacea will be enrolled to have 413 in the modified intent-to-treat mITT population and 371 in the per-protocol PP population. Patients should have fewer than 3 facial inflammatory lesions, and moderate to severe erythema according to both Clinicians Erythema Assessment CEA and Patients Self-Assessment PSA. 